Should a female patient with a first-degree relative with Wolff‑Parkinson‑White syndrome, a normal baseline electrocardiogram without delta waves, and recurrent syncope accompanied by tachycardia be referred for an electrophysiology consultation?

EP Consultation is Strongly Indicated

Yes, an electrophysiology consultation is absolutely appropriate and should be pursued for this patient with syncope and tachycardia, regardless of the absence of delta waves on her baseline ECG or family history of WPW. The presence of syncope accompanied by tachycardia represents symptomatic arrhythmia that warrants expert evaluation and risk stratification.

Primary Rationale

The patient's symptoms—not the ECG pattern or family history—drive the need for EP consultation. Syncope with tachycardia in any patient requires investigation for potentially life-threatening arrhythmias 1. While the family history of WPW raises consideration of an accessory pathway, the absence of delta waves does not exclude:

• Concealed accessory pathways (conduct only retrogradely, showing no pre-excitation on baseline ECG)
• Intermittent pre-excitation (pathway conduction varies with autonomic tone)
• Other arrhythmogenic substrates entirely unrelated to WPW

Key Clinical Considerations

Why the Normal ECG Doesn't Exclude Risk

• Approximately 20-22% of patients with WPW syndrome experience syncope, and this correlates with rapid tachyarrhythmias rather than specific baseline ECG features 2, 3
• Studies show that patients with syncope do not necessarily have distinct baseline electrophysiologic profiles on surface ECG compared to those without syncope 3
• The critical risk factor is the occurrence of atrial fibrillation with rapid ventricular response, which can only be definitively assessed through EP study 2

What EP Study Will Accomplish

The electrophysiology study serves multiple essential purposes in this symptomatic patient:

• Risk stratification for life-threatening arrhythmias: EP study can identify patients at risk for rapid ventricular response during atrial fibrillation (shortest RR interval ≤220 ms), which strongly correlates with syncope and sudden cardiac death risk 2
• Definitive diagnosis: Determines whether an accessory pathway (concealed or otherwise) exists and characterizes its properties 1
• Guides therapeutic decisions: Identifies whether catheter ablation is indicated, which has shown dramatic risk reduction (relative risk reduction of 0.08 for arrhythmic events) 1
• Excludes other arrhythmias: In 11-17% of cases, the presumed culprit pathway is not responsible for clinical tachycardia, and additional clinically significant information is obtained 4

Evidence-Based Approach

Guideline Recommendations

The ACC/AHA/HRS guidelines emphasize that patients with pre-excitation who develop arrhythmia-related symptoms should seek medical expertise 1. While these guidelines focus on asymptomatic pre-excitation management, your patient is distinctly symptomatic with syncope and documented tachycardia, placing her in a higher-risk category requiring evaluation.

Risk Stratification Data

• In young patients with WPW syndrome, sustained atrial fibrillation during EP study had 64% sensitivity and 100% specificity for history of syncope 2
• All patients with syncope and atrial fibrillation had shortest RR intervals ≤220 ms during pre-excited atrial fibrillation, versus only 26% of those without syncope (p<0.001) 2
• The only predischarge variables correlating with subsequent arrhythmias were history of documented arrhythmias and inducible supraventricular tachycardia at EP study 5

Common Pitfalls to Avoid

Do not be falsely reassured by the normal baseline ECG. The absence of delta waves does not exclude:

• Concealed accessory pathways that participate in reentrant tachycardias
• Intermittent pre-excitation
• Other serious arrhythmogenic conditions causing her symptoms

Do not delay referral based on family history alone. While the family history raises suspicion for WPW, her symptoms of syncope with tachycardia warrant EP evaluation regardless of genetic predisposition 6, 7.

Do not attempt empiric antiarrhythmic therapy without EP study. Autonomic function can markedly affect accessory pathway function and even counteract antiarrhythmic drugs, leading to frequent treatment failures 8. Additionally, certain medications (like AV nodal blocking agents) can be dangerous if pre-excited atrial fibrillation is present 9.

Clinical Bottom Line

This patient requires EP consultation based on her symptoms alone. Syncope with tachycardia represents a potentially life-threatening presentation that demands expert evaluation, risk stratification through EP study, and consideration of definitive therapy such as catheter ablation if a high-risk substrate is identified 1, 2. The normal baseline ECG should not delay this referral.